Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat plus High Dose IL-2 in Advanced RCC
NCT03501381Phase 2Active, not recruiting
- Start
- May 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in renal cell carcinoma (RCC). Started May 2018; status: active, not recruiting.
02
Drugs
entinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03501381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501381.